# 502837664 06/04/2014

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT2884260

SUBMISSION TYPE:			NEW ASSIGNMENT			
NATURE OF CONVEYANCE:		ASSIGNMENT				
NATURE OF CONVETANCE:			ASSIGNMENT			
CONVEYING PARTY D	ΑΤΑ					
			Name		Execution Date	
ACTION MEDICINES, S	S.L.				11/15/2011	
RECEIVING PARTY DA						
Name:	1	RMA F	PHARMACEUTICALS, LLC			
Street Address:	_		HWAY 22 EAST			
Internal Address:	SUITE 1	_				
City:	BRIDGE	_	TER			
State/Country:	NEW JE					
Postal Code:	08807					
PROPERTY NUMBERS	5 Total: 1					
Property Type			Number	7		
Application Number:		13154	164			
	e sent to provided	; if th	e-mail address first; if that is un nat is unsuccessful, it will be se ohy@dsiplaw.com			
Correspondent Name:	9	SERV	VILLA WHITNEY LLC			
Address Line 1:			OOD AVENUE SOUTH			
Address Line 2: Address Line 4:			ND FLOOR, SUITE 210			
			N, NEW JERSEY 08830			
ATTORNEY DOCKET N			AMD0003-01CT			
NAME OF SUBMITTER:			KAREN M. WHITNEY			
SIGNATURE:			/Karen M. Whitney, Reg. #52355/			
DATE SIGNED:			06/04/2014			
Total Attachments: 11 source=00227409#page1 source=00227409#page2 source=00227409#page3 source=00227409#page4	2.tif 3.tif					
source=00227409#page5	5.tif					

source=00227409#page6.tif

source=00227409#page7.tif	
source=00227409#page8.tif	
source=00227409#page9.tif	
source=00227409#page10.tif	
source=00227409#page11.tif	

#### PATENT ASSIGNMENT

This PATENT ASSIGNMENT (this "Assignment"), dated as of // November, 2011, is made and entered into by and between Action Medicines, S.L., a company organized under the laws of Spain ("Assignor"), and AmDerma Pharmaceuticals, LLC, a Delaware limited liability company ("Assignee"). Unless otherwise defined herein, all capitalized terms used in this Assignment shall have the meanings set forth in that certain Purchase Agreement, dated as of  $/\int$  November, 2011 (the "Purchase Agreement"), by and among Assignor, DermAct Pharmaceutical, Inc., a Delaware corporation ("DermAct") and Assignee.

WHEREAS, concurrently with the execution and delivery of this Assignment, Assignor, DermAct and Assignee are consummating the transactions contemplated by the Purchase Agreement.

NOW, THEREFORE, for good and valuable consideration as listed in detail in Section 4 of the Purchase Agreement, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

Assignment. In accordance with and subject to the terms and conditions of the 1. Purchase Agreement, Assignor does hereby acknowledge that it has sold, assigned, and transferred, and by these presents does hereby sell, assign, and transfer, unto Assignee, its successors, legal representatives, and assigns, Assignor's entire right, title, and interest throughout the world in, to, and under the patents and patent applications listed in Exhibit A attached hereto (the "Patents and Patent Applications"), including without limitation all patents and patent applications claiming priority to and/or benefit of the Patents and Patent Applications including but not limited to divisions, continuations, and continuations-in-part thereof and all reissues, reexaminations, and extensions thereof, and all priority rights under the International Convention for the Protection of Industrial Property for every member country, and all applications for patents (including without limitation related rights such as utility-model registrations, registrations, inventor's certificates, and the like) heretofore or hereafter filed in any country/countries foreign to the United States, and all patents (including all extensions, renewals and reissues thereof) granted for in any country/countries foreign to the United States. In addition, Assignor does hereby sell, assign, transfer and convey to Assignee, its successors, legal representatives, and assigns all claims for damages and all remedies arising out of any violation of the rights assigned hereby that may have accrued prior to the date of assignment to Assignee, or may accrue hereafter, including, but not limited to, the right to sue for, collect, and retain damages for past infringements of the said patents and patent applications before or after issuance. Assignor hereby authorizes and requests the United States Commissioner of Patents and Trademarks, and any officials of countries foreign to the United States whose duty is to issue patents on applications as aforesaid, to issue all Letters Patents resulting from the Patents and Patent Applications in the name of Assignee, its successors, legal representatives, and assigns, in accordance with the terms of this Assignment.

2. <u>Further Assurances</u>. AM further agrees that it will at any time and from time to time, at the request of AmDerma, execute and deliver to AmDerma all other and further instruments reasonably necessary to vest in AmDerma the right, title and interest in the Patent which this instrument purports to transfer to AmDerma.

2. <u>Limitation</u>. Notwithstanding anything to the contrary contained herein, the Assignee does not hereby assume or agree to perform or pay any liabilities or obligations of either Assignor that are not Assumed Liabilities.

3. <u>Amendments</u>. This Assignment may only be amended by a writing signed by each Assigner and Assignee.

4. <u>Counterparts</u>. This Assignment may be executed in counterparts, each of which shall be deemed an original and all of which shall constitute a single document.

5. <u>Delivery Pursuant to Purchase Agreement</u>. Notwithstanding anything to the contrary herein, Assignor and Assignee is executing and delivering this Assignment in accordance with and subject to all of the terms and provisions of the Purchase Agreement. To the extent of any conflict between the terms and conditions of this Assignment and the terms and conditions of the Purchase Agreement, the terms and conditions of the Purchase Agreement shall govern, supersede and prevail.

6. <u>Binding Effect</u>. This Assignment shall be binding upon, and shall inure to the benefit of, Assignors and Assignee and their respective successors and assigns.

7. <u>Governing Law</u>. This Assignment shall be governed by and construed in accordance with the laws of the State of New Jersey, without regard for conflicts of laws principles.

[SIGNATURE PAGE FOLLOWS]

《北北部新疆东北东 机碱人 医二十分分子

#### PATENT REEL: 033029 FRAME: 0234

IN WITNESS WHEREOF; this Assignment	has been duly executed and delivered by the
and the second of the second second second	or our parameters as
$(\phi, \phi, \phi, \phi) \in \{1, 1, 1, 1, 1, 1, 1, 2, 1, \dots, n\} $	ASSIGNOR: TO THE DESTRICT OF A
the end of ending the second of the second of	the description of a spanning
$+ a \cos(\theta + 1) \sin(\theta + \theta) + \sin(\theta + \theta) + \sin(\theta + 1)$	ACTION MEDICINES, S.L.

1,111

is more than a provide set of the set of providence of in and the stand the new terms of the Bry: Main and the en la companya de la

Name: Santiago de Gracia Title: CEO-Consejero Delegado

Sign in presence of a Notary and have Notary attach Acknowledgement

**ASSIGNEE:** AMDERM# PHARMACEUTICALS, LLC

By: Name: Chirag Patel Title: Manager and Prosidet

Sign in presence of a Notary and have Notary attach Acknowledgement

Attorney at Law Istate of NJ Anshu Pathak, ssq.

SIGNATURE PAGE TO PATENT ASSIGNMENT

PATENT · / · · REEL: 033029 FRAME: 0235 ../... T I M A C I O N: -----

YO, MIGUEL KRAUEL ALONSO, Notario de Málaga, Ilustre Colegio de Andalucía .-----

VISTA Y LEGITIMADA: Doy fe que la firma y rúbrica que precede de DON SANTIAGO DE GRACIA CLEMENT con D.N.I./N.I.F. número 00100848-Q, la considero legitima por haber sido puesta a mi presencia y haberle identificado por su reseñado documento, que me exhibe y le devuelvo.-

En Málaga, a veintitrés de septiembre de dos mil once . APLICACION ARANCEL LEY DE TASAS HONORARIOS: 6,16  $\in$ LIBRO INDICADOR: Hoja N°  $\sim 260$  Section 2<sup>a</sup>



# EXHIBIT A

# то

### PATENT ASSIGNMENT

# (See Attached)

ĉ

4 15

Ref				E 10 1 5 1 1 1 1		4 6 2 4 3 8 20 6	a carta c
No. +	Title of Invention	Country	Status	Appln No.	Filed	Patent No.	Issued
	A HER OF THE PARAMETER	Country	GLACUS	Appen aver	8/2/2006	THE PARTY AND A	*13011-00
	Use of Dihydroxy-		이는 이는 것이 있는 것이 가지? 같은 이 이렇게 가지 않는 것이 있는 것이 있는 것이 있는 것이 있는 것이 있는 것이 있는 것이 같이 있는 것이 같이 있는 것이 있는 같은 이 이 이 이 이 이 있는 것이 없는 것이 있는 것이 있는 것이 없는 것이 있는 것이 있는 것이 있는 것이 있는 것이 있		PCT Filing		
	benzenesultonic acids.		Response to		Dete		
	in the Production of.		non-final GA		2/16/2005		. Ale 1998
가 다 가 있다. 1917년 전	Medicaments for				Priority		
	Angiogenic Diseases		6/30/2010		2/16/2005	US20080293816	$\{0, \dots, V\}$
2021	Psottasis	US	awaiting to PTO action	10/588.166	(PCT Filing) 2/17/2004	11/27/2008	
1.1	Use of Diliverocy-	00	I LO BOUDI	107300,100 ····	- 27 F 76 20 00 T	a and Sancord and	
lut A	benzenesultonic acids	945.23			11 : 말라		$\mathcal{F}_{\mathcal{F}}$
8	in the Production of						見て対象
P2280	Medicaments for			[ 영화 25 m]			
	Anglagenesis-	化现物	Granted	EP05708114			
P	dependent Diseases	Belgium	Validated	<b>3</b> .	16/02/2005	EP1719509	
	Lise of Dihydroxy- benzenesülfonic acads		and a line of the second	1. 法资格。			<b>国际</b> 交往
1. 18	in the Production of				医子宫 類	的。我的问题。	
P2280	Medicaments for						
3DEE	Angiogenesis-		Granted	EP05708114	1.1	i i di	
P	dependent Diseases	Germany	Validated	<u> </u>	16/02/2005	EP1719509	$\mathcal{A} \in \mathcal{A}$
11,617	Use of Dihydroxy-			· 二的 國家 (第)			
「「読む学生」 「読む学生」	benzenesulfonic acids			thing the set			气化剂 的第
P2280	Medicaments for					E01719509	
3DKE	Angiogenesis		Granted	EP05708114		DKIEP 1719509	「大学」の
Р	dependent Diseases	Denmark	Validated	1. Sec. 1. Sec	16/02/2005	1 <b>1 1</b>	
	Use of Dinydroxy		1.12.16.211-0				
	benzenesultonia acids						清空增长
P2280	Medicaments for					김 강남 김 영	
SESO	Angiopenesis			P200400371			التوقي والمراج
0	dependent Discases	Spein	Granted	5	17/02/2004	ES2238924AB	
13.23	Use of Dihydmxy-	探告				A STATE OF	
9	ocuzencsulfonic acids						
1	in the Production of	한 것 것 것					
P2280 3ESE	Medicaments for		Granted	EP05708114	机塑料 (第二)读 1.思大的第三人	EP17/9509	
p	dependent Diseases	Spain	Validated	1103300114	16/02/2005	152334447E3	
	Use of Dinveroxy-				1 10		
	benzenesultonie acids			1 74.58	n grig ta di di di		
n	in the Production of					NAR PAGE	
P2280	Medicaments for				「終えます」「お		승만 아주 우리
3FRE P	Anglogenesis dependent Diseases	Finance	Granted	EP05708114	16/02/2003	ap the second and the second	35 S Y S
F	Use of Dihydroxy-	TEMPOR	wanning	<u>l v ve vve r</u>	10/02/2000	EP1719509	
	benzenesalfonic acids				[1] 医紫癜		當時之一
L. C. A	in the Production of						
	Medicaments for	自己的 梦	Ren and	1.2 月前			
3GBE	Angiogenesis	United	Granted	EP03708114			
P	dependent Diseases	<sup>3</sup> Kingdom	Validated	<u>13</u>	16/02/2005	EP1719509	
P2280	Use of Dihydroxy-		S. Casarat	EP05768114		int the	
P June -	benzenesülfünie acids in the Production of	la ≥tra sur la	Granted Validated	1212105708114	16/02/2005	Sep1710500	
	, armenneuwruh (3	-pr	, vanualuo	3.55.75 <sup>.02</sup> (-1)	1.00002020210	10 SELECT 1 1 7 10 7	يترقل بتحميقك

A474132456.1

٩,

1

n

PATENT REEL: 033029 FRAME: 0238 and the second states of the

·				and the second s	Contraction of the second s	NAMES AND STRACT AND	<u></u>
1. 1.	Medicaments for		化化化化 机	San Salata		이 집에 있는 것이 같아.	
	Angiogenesis dependent Diseases				말한 날 가슴 옷		
	Lise of Dihydroxy-		4		1 <u>77</u> 177		
	bonzenesulfonic acids				이 않는 것		
$\sim 1^{44}$	brithe Production of			马马拉 医子宫	S 8 8 8 8		19 2 2 2
P2280	Medicaments for		에는 이상에 관하는 것 이 가장 것이 있는 것이 있 같이 있는 것이 같이 있는 것이 있는 것				요즘 않는다.
3ITE	Angiogeocsis-		Granied	EP05708114		EP1719509	
P	dependent Diseases	Italy	Validated	a she ta she ta	16/02/2005	47515BE2010	
	Use of Dihydroxy-	10					
	benzenesulfonic acids						2 2 2 2 2 2 A
	in the Production of					an 2825 966	1003
P2280	Medicarcents for	Netherian		EP05708114		and a second second Manufacture second s Manufacture second s	
3NEE P	Anglogenesis- dependent Diseases	Netherian	Granted Validated	EPUD/08114	16/02/2005	EP1719509	
E .	Use of Dihydroxy-		** AIRIBICU		10/02/2003	251 891 <b>7207</b>	
	benzenesultonic acids					15 A.	
1 2 4 4	in the Production of				с <sup>у</sup> — 2		
P2280	Medicaments for			n de la Reinsteine En de Margares de	1. S. A. S.		
SPTE	Anglogenesis-		Granted	EP05708114			
<u>P</u>	dependent Diseases	Portugal	Validated	3	16/02/2005	EP1719509	1994
a - 5	it be of Dinydroxy-						
1.1	benzenesülfümic acids						E 관고 -
	in the Production of Medicaments for				10		ξ
P2803	Angiogenesis		Granted	EP05708114			
SEEP	dependent Diseases	Sweden	Validated	3	16/02/2005	: EP1719509	
	Use of Dihydroxy-						
	benzenesulicinic acids		ोस्स क्यू किंद्य का उन्हों। जनकी संविध का जिल्हा	in an Allandar Na Stationa		losi − Santa S Santa Santa Sant	
1	m the Production of					이 중품 날랐다. 관	
P2803	Medicaments for						
AUP	Angiogenesis	Australia		2005211956	16/02/2005		
	dependent Diseases	Austrina		2003211930	10/02/2005	n an	
1 1 1	Denzenesulfonic acids	1913) B. 1911 (A	1. 1. 2 4 1. 19 14		<b>长</b> 、13月3天	1983年1月1日日本 建	
1	in the Production of		【19】 "小说了"风深的情 【19】 "小儿"了"风"。"你		化合成 建石		國際的於
P2803	Medicaments for					이에는 물질을 줄	「小人文」
CAP	Angiogenesis-		1993				
C	dependent Diseases	-Canada	<u> </u>	2:555.246	16/02/2005		
i i	Use of Dinydroxy-				1.18 8 33		
	benzenesuitonic acids		資料 調報 湯り				
P2803	Medicaments for			·注意 法要问			
CNP.	Angiogenesis			2005800051		1. 新闻》: 1. 新闻 1. 新闻》: 1. 新闻	化试验器
16 <sup>-2</sup>	dependent Diseases	China		87.3	16/02/2003	CN 101014330A	
1	Use of Dihydroxy-	1.1.1.1.5	7 and gen a light	in al a	the start	Strates in	
1917	benzenesulfonie acids	[20]清子:"新 [15]云:"新山市			観日 可心	14 - 時間には	
	in the Production of	本調驗診	1. 物"感"的	國際的資源			[ 14 1 4 4
- Mannin	Medicaments for	L 42, 73			「「「素積の	1. 私代行用	[ 1] 평균 1
P2803	Angjogenesis	İsrael		177238	16/02/2003	化乙酸磷酸盐	白頸症
	dependent Diseases		2321 - <u>2</u> 2 2321 - 24	1 14 2:35	10/02/2005	t see the second se	17 <u>11</u> 7 1711 187
N	benzenesulfonie acida		警告: 論明:			a fill der regelennen -	也的感到
P2803	in the Production of	國際自由		2006-		1963年7月1日,1963年1月1日 1963年1月1日日(1963年1月1日) 1963年1月1日(1963年1月1日)	[1]: 水心发射 [1]: 水心发射
IPPC	Medicaments for	E Iapan		553602	716/02/2005	的复数 外球分离	al de la compañía 19 de aostro de la compañía 19 de aostro de la compañía
	اجازه برزار ومستحد ومستحدة والمستحدة والمراجب المتحداث		بالحاذا المستعصف الا	فسنست المستحد المعادية	الاحتياد والمستحد والمستحد والمحالة	فالانتهاد فالمنتق شندست بالمتعاط متصفح والم	

A774152456.1

, e

4	Angiogenesis- dependent Diseases						
1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	Use of Dinydraxy- benzenesilfonic acids.						
P2803	in the Production of Medicaments for						
MXP C	Angiogenesis- dependent Discusses	Мсхісо	Granted	PAta120061 009295	16/02/2005	269609	
1	Use of Dihydroxy- benzenesulforme.acids						
P2803	in the Production of						
UAP C	Angiogenesis dependent Diseases	Ukraine	Granted	2006 091271M	16/02/2005	<b>\$6399</b>	
					8/16/2006 CIP.of		
		14.195 (1917) 1917 - 1985 (1917)			10/588,166 above, filed		
	Methods of use for		Response to final Office		8/2/2006 (Nul) Phase		
「大き殺」	2.5-dihydroxyberizene: sulfonie acid		Action and RCE filed		Filmg) 2/16/2005		
	compounds for the Treatment of Cancer,		12/28/2009		(PCT) Filmg),	US20070149618	
202.2	Rosacea and Psoniasis	E US A	aciton .	11/506:469	2/17/2004 8/15/2007	Pub.date 6/28/2007	
					8/16/2006 and CIP of		
					bove filed		
					8/16/2006 which is CIP		
1000 1000 1000 1000 1000 1000 1000 100			Notice of Appeal filed		10/588,166 above filed		
			4/15/2010 Response to final OA md		8/2/2006/Na 01 Phase		
1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.	Lise of Dihydroxy-		RCE flue		Filing)		
	derivatives for		(6/7) FINAL		(PCT-	US20080123485	
202	Keratosis	ill's	41/15/20107/17)	1,1/839,508	2/17/2004 Divisional	Fub.date 5/29/2008	
					11/506,469,		
2 m 1 1					above filed 18/16/2006		
the state	지하는 것을 가지 않는 것을 가지 않는 것을 가지 않는다. 이 가지 않는 것을 가지 않는 것을 가지 않는다. 이 가지 않는 것을 하는 것				whin is a CIP of		
	Methods of use for 2.5-dihydroxybenzeric				10/588.166,		
	sutionic acid		Pending		48/2/2006(Na		
2023	Treatment of Catter, Rosacea and Psoriasis	us in	awaiting PTO	12/257-854		US20090111779	

KJ74.(52456;)

PATENT REEL: 033029 FRAME: 0240 The second se

		PCT Piling Date 2717/2004
Use of Dihydroxy- brizonesulfonts dorivatives for P3195 frening Activity EPPC Kontosis	EP07788425	\$/15/2007 BP2054651

A/74152456.1

COMPOUND FALMINIS							
Ref No.	Title of Invention	Country	Status	Appin No.	in Filed	Patent No	lisued
		的傳	Final OA mailed 17/1/2010				
			Response to				
	Use of Dihydroxy- benzenesulfonic derivatives for		10/1/2010 (1/6) Final deidline			US20080114075	
203	Treating Dermatitis	US	(5/6)	11/839,51- 2	8/16/2005 7/2/2007	Pub.detc \$/15/2008	
	Use of Dihydroxy- benzenesulionic derivatives for						
P319 6EP PC	Treating Dematics	ÊU		EP077884 26.0	B/15/2007	EP2056815	
			Final OA mailed 5/5/2010			1. State of the second s and second s second second secon second second sec	
			Response to - Bnal OA and -				
	Use of 2.5- dihydroxybenzene compounds and		RCE 10/5/2010 (5/6) Fmail				
	Derivatives for the Treatment of		deadline 11/5/2010	11/839,51	8/16/2006 (7/2/2007	US20080113947 Buildete	
204	Rosicca Lise of Dihydroxy-	US	16/69	17 ( <b>)</b> 17 ()		5/15/2008	1.1 读言: "这一字,是一字
9319 8EP	benzenesti fonic derivatives for the Description of			EP077884			
<b>PC</b>	Rosacea	i d <b>eu</b> de la composition de l	Final OA	28.6	2 <b>8/15/2007</b>	EP2056813	
			mailed 5/21/2010 Response to				
	Use of 2.5-		final OA and RCE				
	dihydroxybenzene Compounds and Derivatives for the		10/21/2010 (5/6) Final detelline			US20080113948	
205	Treatment of Psonaais	US	-11/21/2010 (6/6)	14/839.52 0	8/16/2006 7/2/2007	Pub.date 5/15/2008	andan Antonio (1997) Antonio (1997)
P319	Use of Dihydroxy- ibenzonesulfonic derivatives for the	Ale Al Galeria Al Galeria Al Marca Ale					
9EP PC	Treatment of Psoriasis	ΞŪ		EP077884 29.4	8/15/2007	EP2056814	
	Use of 2.5- dihydroxybenzene tompounds and		Response filed		2004 1		
الله م وليدين تشر متابع لا	Derivatives for the Treatment of Skin.		7/26/2010 awaiting PTO,		8/16/2006	US20080174060 Fub.date	
206	Cancer	田花US 黛麗	action	1 2 > 1	1.972/2007.2	5/15/2008	1.453533

A/74152456.3

Skin Peretiation Enfancing 210 Systems for Polar Drugs UU	Filurg date 2/(7/2009 Priority) 2/15/2008 (US Pending) (National) (National) 1) Stage Ensemed 12/867/87 5 8/16/2010) 5 NA
Processes for the Preparation of 2.5- Minydroxynanzene	Peading Peading (National Stage Entered 12/811.62 / 1/2/2009
212 J sulfonic Acid Salts 1. U	8 🖬 1 (772/2010) 🖓 1 - Mail - Al Sandar - Al Markin Markin (1997) (1997) - Al Sandar - Al Markin (1997) (1997) - Al Markin (1997) (19

· · ·

<u>\$774</u>]\$2456;1

· · · ·

.

· · · · · · · · ·

• •

.

.

.

States of the

RECORDED: 06/04/2014